May 7, 2012 — The American Recovery and Reinvestment Act (aka, “the stimulus package”) provided AHRQ with $29.5 million for a program on academic detailing and the “communication of CER results to physicians.” One contract, for $11.7 million, went to Total Therapeutic Management (TTM) and is specifically intended for physician outreach and education. (TTM is […]
Read moreTag: CER
CERRefuting Inaccurate CER Results Is “Right” of Drug Sponsors, Temple Says
Feb. 13, 2012 – Dr. Robert Temple, the unofficial dean of drugs at the FDA, recently addressed one of the most perplexing issues in the post-health reform era – industry’s ability to fully participate in policy and pricing discussions on comparative effectiveness research (CER). Companies are well aware that false or misleading CER findings can […]
Read more